İbrahimPetekkaya
Doç. Dr. İbrahim Petekkaya
Tıbbi Onkoloji


  • Görev Aldığı Lokasyon :
        Tınaztepe Hastanesi
  • Görev Aldığı Bölüm :
       Tıbbi Onkoloji
  • Yabancı Diller :
       İngilizce

Çalışma Saatleri


Pazartesi 9:00-17:00

Salı 9:00-17:00

Çarşamba 9:00-17:00

Perşembe 9:00-17:00

Cuma 9:00-17:00


Doç. Dr. İbrahim Petekkaya

Eğitim:

1993 - 2000 : Atatürk Üniversitesi Tıp Fakültesi

Uzmanlıklar:

2003 - 2008 : Çukurova Üniversitesi Tıp Fakültesi, İç Hastalıkları Uzmanlığı

2010 - 2013 : Hacettepe Üniversitesi, Tıbbi Onkoloji Uzmanlığı

Tıpta Uzmanlık Tezi:

Non-Hodgkin Lenfomalı hastalarda tedavi öncesi ve sonrası ( 3 ay) CD4, CD8, CD20, CD25, CD56  ve Akut Faz Reaktantları (C-Reaktif Protein, Ferritin, Prokalsitonin) IL1, IL6, TNFα düzeylerinin değerlendirilmesi, Adana 2008.

Yan Dal Uzmanlık Tezi:

Opere edilebilir meme kanserli hastalarda Enflamatuvar Markerların Prognoz üzerine etkisinin incelenmesi, Ankara 2013.

Görev Yerleri:

2008 - 2009 : Diyarbakır Çermik Devlet Hastanesi İç Hastalıkları uzmanlığı Devlet Hizmet Yükümlülüğü

2009 - 2010 : GATA Ankara Acil Tıp, İç Hastalıkları

2013 - 2015vGaziantep Dr. Ersin Arslan Devlet Hastanesi (Tıbbi Onkoloji)

2015 - 2016 : Özel Eskişehir Sakarya Hastanesi

2017 -          : Özel Tınaztepe Hastanesi

Görevler:

2010-2012  : Türk Tıbbı Onkoloji Derneği yandal asistan temsilciliği yandal asistan temsilciliği görevi
Türk Onkoloji Grubu Genç Araştırmacılar Grubu Başkanlığı- Halen görevde

Projelerde Yaptığı Görevler 

1. Türkiye’deki inflamatuvar meme kanserli hastaların klinik, demografik özellikleri ve prognostik faktörler.TOG genç araştırmacılar projesi. Proje sorumlusu Prof. Dr Pınar Mualla Saip

Üyelikleri:

Türk Tıbbi Onkoloji Derneği
Türk Onkoloji Grubu
European Society of Medical Oncology

Ödüller:

1. En İyi Çalışma Birincilik Ödülü.  Fatma P. Türköz, Mustafa Solak, Özge Keskin, İbrahim Petekkaya, Furkan Sarıcı, Kadri Altundağ. Luminal, Her-2 Pozitif Ve Triple negatif alt tiplerin gelişiminde bilinen meme kanseri risk faktörlerinin aynı etkiye mi sahiptir ? 4. Tıbbi Onkoloji Kongresi Bildiri Değerlendirme Komitesi. 21-25 mart 2012 , Antalya.

2. Sözlü Bildiri Ödülü.Taner Babacan, Taha Yusuf Kuzan, Furkan Sarıcı, Ozan Balakan, Uğur Şahin, İbrahim Petekkaya, Kadri Altundag  Renin-Angiotensin-Sistemi (Ras) İnhibisyonunun Patolojik N3a Grubu Meme Kanseri Hastalarında Sağkalım Ve Nüks Üzerine Etkisi,  9. Ulusal Onkoloji Kongresi, KKTC,12-16 Eylül 2012, Poster No: 130

Eserler:

A-Uluslararası hakemli dergilerde yayımlanan makaleler:

A1-Petekkaya I, Sahin U, Gezgen G, Solak M, Yuce D, Dizdar O, Arslan C, Ayyildiz V, Altundag K. Association of breast cancer subtypes and body mass index. Tumori. -Apr;99(2):129-33. doi: 10.1700/1283.14180.

A2-Dogan E, Yorgun H, Petekkaya I, Ozer N, Altundag K, Ozisik Y. Evaluation of cardiac safety of lapatinib therapy for ErbB2-positive metastatic breast cancer: a single center experience. Med Oncol. 2012 Dec;29(5):3232-9.

A3-Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, Arik Z, Babacan T, Ozisik Y, Altundag K. Association between common risk factors and molecular subtypes in breast cancer patients. Breast. 2013 Jun;22(3):344-50.

A4- Petekkaya I, Ayyildiz V, Kizilarslanoglu MC, Sahin U, Gezgen G, Roach EC,Karcaaltincaba M, Altundag K. Prognosis of breast cancer in patients with peritoneal metastasis. Breast. 2012 Jun;21(3):420-1.

A5-Gezgen G, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K. Metabolic syndrome and breast cancer: an overview. J BUON. 2012 Apr-Jun;17(2):223-9. Review.

A6-Turkoz FP, Solak M, Aksoy S, Petekkaya I, Keskin O, Kertmen N, Sarici F, Arik Z, Babacan T, Simsek E, Ozisik Y, Altundag K. Association between family history and clinicopathologic characteristics in 1987 breast cancer patients: single

institution experience from Turkey. J BUON. 2012 Oct-Dec;17(4):649-57.

A7- Petekkaya I, Gezgen G, Roach EC, Solak M, Gullu I. Long-term advanced cholangiocarcinoma survivor with single-agent capecitabine. J BUON. 2012 Oct-Dec;17(4):796.

A8-Kertmen N, Sahin U, Keskin O, Solak M, Petekkaya I, Babacan T, Sarici F, Arik Z, Kizilarslanoglu B, Altundag K. Comparison of clinicopathological characteristics and outcome of younger and older breast cancer patients. J BUON. -Dec;17(4):797.

A9-Kuria IM, Petekkaya I, Hasanov E, Babacan T, Dizdar O, Altundag K. Joint problems in breast cancer patients receiving adjuvant aromatase inhibitor. J BUON. 2012 Oct-Dec;17(4):798-9.

A10- Petekkaya I, Akin T, Gezgen G, Roach EC, Ozisik Y, Altundag K. Electrolyte abnormalities due to irinotecan administration in metastatic HER-2 positive breast cancer patients. J BUON. 2012 Oct-Dec;17(4):800

A11-Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr Med Res Opin. 2013 Apr;29(4):405-14.

A12-Sarici F, Babacan T, Petekkaya I, Gezgen G, Roach EC, Altundag K. Colon involvement in a chronic lymphocytic leukemia patient. J BUON. 2013 Jan-Mar;18(1):291-2.

A13- Vural O, Dizdar O, Petekkaya I, Alnak A, Babacan T, Altundag K. Frequency of thyroid disease among breast cancer patients: a descriptive study of breast cancer patients. J BUON. 2013 Jan-Mar;18(1):294-5.

A14-Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, Arik Z, Babacan T, Ozisik Y, Altundag K. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women. J BUON. 2013

Apr-Jun;18(2):335-41.

A15-Petekkaya I, Babacan T, Sarici F, Gezgen G, Roach EC, Kizilarslanoglu MC, Altundag K. Medullary carcinoma of the breast: a brief report from a tertiary care center. J BUON. 2013 Jul-Sep;18(3):798.

A16- Keskin O, Aksoy S, Babacan T, Sarici F, Kertmen N, Solak M, Turkoz FP, Arik        Z,Esin E, Petekkaya I, Altundag K. Impact of the obesity on lymph node status in operable breast cancer patients. J BUON. 2013 Oct-Dec;18(4):824-30.

A17-Akpinar E, Ayyildiz VA, Petekkaya I, Erbil B, Dogra V. Fluid rim sign: a new ultrasonographic sign of soft tissue aspergillosis. Diagn Interv Radiol. 2013 May-Jun;19(3):237-9.

A18-Petekkaya I, Aksoy S, Roach EC, Okoh AK, Gecmez G, Gezgen G, Isler DC, Dogan E, Babacan T, Sarici F, Petekkaya E, Altundag K. Impact of inflammatory markers on the prognosis of patients with operable breast cancer. J BUON. 2014 Jul-Sep;19(3):673-80.

A19-Tulay AKMAN, Ozgur TANRIVERDI, Mehmet A. OZTURK, Ibrahim PETEKKAYA, Hakan BAKKAL, Ozlem U. SONMEZ, Nilufer AVCI, Seyda ZENGIN, Gorkem AKSU, Gokhan OZYIGIT, Huseyin ABALI.  A View from Young Oncologists on Clinical Trials in Turkey: Obstacles and Solution Proposals.UHOD , 2014 , 24 , 001-007

A20-Roach EC, Petekkaya I, Altundag K. Behcet's disease and breast cancer. Breast J. 2014 Sep-Oct;20(5):566-7. doi: 10.1111/tbj.12320. Epub 2014 Jul 12

A21-Babacan T, Balakan O, Kuzan TY, Sarici F, Koca E, Kertmen N, Petekkaya I, Altundag K. The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+ breast cancer patients. J BUON. 2015 Jan-Feb;20(1):50-6.

A22-Roach EC, Petekkaya I, Gezgen G, Ünlü O, Altundag K. Serpentine supravenous hyperpigmentation resulting from vinorelbine administration. Breast J. 2015 May-Jun;21(3):311-2. doi: 10.1111/tbj.12405. Epub 2015 Mar 23.

A23-Altuntaş O, Petekkaya İ, Süslü N, Güllü İ. Renal cell carcinoma metastatic to the tongue: a case report and review of the literature. J Oral Maxillofac Surg. 2015 Jun;73(6):1227-30. doi: 10.1016/j.joms.2014.12.031. Epub 2015 Jan 8. Review.

A24-Turan N, Benekli M, Unal OU, Unek İT, Tastekin D, Dane F, Algın E, Ulger S, Eren T, Topcu TO, Turkmen E, Babacan NA, Tufan G, Urakci Z, Ustaalioglu BO, Uysal OS, Ercelep OB, Taskoylu BY, Aksoy A, Canhoroz M, Demirci U, Dogan E, Berk V, Balakan O, Ekinci AŞ, Uysal M, Petekkaya İ, Ozturk SC, Tonyalı Ö, Çetin B, Aldemir MN, Helvacı K, Ozdemir N, Oztop İ, Coskun U, Uner A, Ozet A, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma. Chin J Cancer Res. 2015 Aug;27(4):408-16.

A25- Bilir C, Yıldız İ, Bilici A, Ucar M, Berk V, Yıldız Y, Yazıcı O, İmamoğlu Gİ, Karadurmuş N, Pilancı KN, Arpacı E, Tanrıverdi Ö, Karcı E, Temiz S, Nayır E, Oktay E, Dal P, Petekkaya İ, Varım C, Cinemre H. Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study. Cancer Invest. 2017 Apr 21;35(4):248-255. doi: 10.1080/07357907.2017.1292518. Epub 2017 Mar 23. PubMed PMID: 28333566

A26- Petekkaya I, Unlu O, Roach EC, Gecmez G, Okoh AK, Babacan T, Sarici F, Keskin O, Arslan C, Petekkaya E, Sever AR, Altundag K. Prognostic role of inflammatory  biomarkers in metastatic breast cancer. J BUON. 2017 May-Jun;22(3):614-622. PubMed PMID: 28730765.

B.Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings) basılan bildiriler:

B1-Petekkaya I, Arslan C, Dogan E, Solak M, Keskin Ö, Kertmen N, Ozisik YY, Altundag K. Body mass index in breast cancer subtypes. Fortytseventh Annual Meeting of American Society of Clinical Oncology, Chicago, USA, June 03-07, 2011. J Clin Oncol 29: 2011 (suppl; abstr 1117), (Presentation)

B2-Yavuz S, Erkisi M, Petekkaya I, Basel N; Cukurova University Medical School, Adana, Turkey.Important serum markers in malignant lymphoma.Fortyfifth Annual Meeting of American Society of Clinical Oncology. Chicago, USA, June,2009. J Clin Oncol 27, 2009 (suppl; abstr e22225)

B3-Solak M, Turkoz FP, Petekkaya I, Arslan C, Kertmen N, Keskin Ö, Dogan E, Ozisik YY, Altundag MK. Association between blood groups and breast cancer subtype. Fortytseventh Annual Meeting of American Society of Clinical Oncology,Chicago, USA, June 03-07, 2011. J Clin Oncol 29: 2011 (suppl; abstr e11041).

B4-Dogan E, Yorgun H, Petekkaya I, Ozer N, Altundag K, Ozisik YY. Evaluation of cardiac safety of lapatinib therapy for c-erbB2 amplified metastatic breast cancer. Fortytseventh Annual Meeting of American Society of Clinical Oncology, Chicago, USA, June 03-07, 2011. J Clin Oncol 29: 2011 (suppl; abstr e11001).

B5-Petekkaya I, Roach EC, Gezgen G, Unal S, Altundag K. A tricky differential diagnosis- primary pancreatic lymphoma mimicking secondary involvement. 10th European Federation of Internal Medicine Congress, Athens, Greece. Eur J Intern Med 2011; 22 (Suppl 1): S96

B6-Petekkaya I, Ayyildiz V, Kizilarslanoglu C,Sahin U, Gezgen G,Roach E.C,Karcaaltincaba M, Altundag K.Prognosis of breast cancer in patients with peritoneal metastasis.Fortyeight Annual Meeting of American Society of Clinical Oncology. Chicago, USA ,June 01-06, J Clin Oncol 30, 2012 (suppl; abstr e11509).

B7-Altundag K,Petekkaya I,Sahin U, Solak M,Ozisik Y.Non-breast solid malignancies among breast cancer survivors.Fortyeight Annual Meeting of American Society of Clinical Oncology. Chicago, USA ,June 01-06, J Clin Oncol 30, 2012 (suppl; abstr e11092).

B8-Kizilarslanoglu C,Petekkaya I,Babacan T,Altundag K. Nine-weeks of adjuvant trastuzumab in HER2-positive breast cancer: A single center experience. Fortyeight Annual Meeting of American Society of Clinical Oncology. Chicago, USA ,June 01-06, J Clin Oncol 30, 2012 (suppl; abstr e11080).

B9-Sahin U, Petekkaya I, Arslan C, Sarici S.F,Solak M,Keskin O,Ozisik Y,Altundag K. Impact of obesity in postmenopausal early breast cancer patients receiving frontline adjuvant aromatase inhibitors. Fortyeight Annual Meeting of American Society of Clinical Oncology. Chicago, USA ,June 01-06, J Clin Oncol 30, 2012 (suppl; abstr e11020).

B10-Petekkaya I. A, Aksoy S, Gecmez G, Kulahcioglu E, Okoh A K, Isler D C, Demirci A F, Sahin U, Dogan E, Altundag K.  Inflammatory markers in early-stage breast cancer. Forty-ninth Annual Meeting of American Society of Clinical Oncology,Chicago, USA, May 31- June 4, 2013. J Clin Oncol 31, 2013 (suppl;abstr e11537)

B11-Unlu O,  Aygun S, Petekkaya I, Gecmez G, Roach E C, Babacan T, Sahin U, Keskin O, Kertmen N, Aksoy S, Altundag K. Association of the neutrophil to lymphocyte ratio with survival patients with in metastatic breast cancer. Forty-ninth Annual Meeting of American Society of Clinical Oncology, Chicago, USA, May 31- June 4, 2013. J Clin Oncol 31, 2013 (suppl;abstr e11544)

B12-Sahin U, Petekkaya I, Gecmez G, Babacan T, Roach E C, Sarici S F, Arslan C, Arık Z, Aksoy S, Altundag K. Inflammatory markers in metastatic breast cancer. Forty-ninth Annual Meeting of American Society of Clinical Oncology, Chicago, USA, May 31- June 4, 2013. J Clin Oncol 31, 2013 (suppl;abstr e11545)

B13-Solak M, Turkoz F P, Keskin O, Petekkaya I, Sarici S  F, Babacan T, Esin E, Aksoy S, Altundag K. The number of metastatic lymph node in N3MO breast cancer and influence on survival. Forty-ninth Annual Meeting of American Society of Clinical Oncology, Chicago, USA, May 31- June 4, 2013. J Clin Oncol 31, 2013 (suppl;abstr e12563)

C2.Yazılan uluslararası/Ulusal kitaplar veya kitaplarda bölümler:

1.. E.C. Roach, I. Petekkaya, F. İçli, N. Taçyılmaz, D. Kılıç, MD Anderson Tıbbi Onkoloji (METASTATİK MEME KANSERİ),679-710 pp.,İSTANBUL, NOBEL TIP KİTABEVİ, 2014
2.. E.C. Roach, I. Petekkaya,, F. İçli, N. Taçyılmaz, D. Kılıç, MD Anderson Tıbbi Onkoloji (MEME KANSERİNDE ÖZEL DURUMLAR),731-746 pp.,İSTANBUL, NOBEL TIP KİTABEVİ, 2014

D.Ulusal hakemli dergilerde yayımlanan makaleler:

D.1. Ibrahim Petekkaya, Emir Charles Roach, Gamze Gezgen, Musturay Karcaaltincaba, Aysegul Uner, Emine Petekkaya, KadriAltundag, "Primary Pancreatic Lymphoma Mimicking Secondary Involvement". Gaziantep Medical Journal. 2014-03-044